TY - JOUR T1 - Prognostic Role of p53 in Stage III Non-small Cell Lung Cancer JF - Anticancer Research JO - Anticancer Res SP - 2385 LP - 2389 VL - 25 IS - 3C AU - THIERRY BERGHMANS AU - CÉLINE MASCAUX AU - BENOIT MARTIN AU - VINCENT NINANE AU - JEAN-PAUL SCULIER Y1 - 2005/05/01 UR - http://ar.iiarjournals.org/content/25/3C/2385.abstract N2 - Background: New biological factors have not been extensively studied in stage III non-small cell lung cancer (NSCLC). We aimed to determine the role of p53 as a prognostic factor in such patients. Materials and Methods: p53 expression was assessed by immunohistochemistry and evaluated by three independent observers. The Cox model was used to assess the impact of clinical and biological factors on patient survival. Results: Between 01/1987 and 07/2002, 93 stage III NSCLC patients were included. Twenty-eight had a p53-positive tumour. There was no survival difference among patients with p53-positive and -negative tumours (p=0.46). In multivariate analysis, 3 factors were statistically significantly associated with survival: surgical resection (p=0.009), good performance status (p=0.02) and low creatinine level (p=0.02). Conclusion: Good performance status, surgical resection and low creatinine level were independent favourable prognostic factors for survival in stage III NSCLC, while p53 was not, even in univariate analysis. ER -